Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer

OBJECTIVES: To assess cabazitaxel versus docetaxel re‐challenge for the treatment of metastatic castrate refractory prostate cancer (CRPC) patients previously treated with docetaxel at inception of primary hormone therapy. PATIENTS AND METHODS: The CANTATA trial was a prospective, two‐arm, open‐labe...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Nicholas D., Ali, Ayesha, Pope, Ann, Desai, Amisha, Ford, Daniel, Stevenson, Robert, Zarkar, Anjali, Pirrie, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
To the Clinic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579888/
https://www.ncbi.nlm.nih.gov/pubmed/36267204
http://dx.doi.org/10.1002/bco2.177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579888/
https://www.ncbi.nlm.nih.gov/pubmed/36267204
http://dx.doi.org/10.1002/bco2.177

Ejemplares similares